BNTX vs. TEM: BioNTech vs. Tempus AI Stock Comparison

Company Profile

BioNTech (BNTX) and Tempus AI (TEM) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BNTX is classified in Biotechnology while TEM is classified in Life Sciences Tools & Services.

BioNTech (BNTX) has been public since October 10, 2019, giving it a longer listed trading history, while Tempus AI (TEM) listed on June 14, 2024 and still has a shorter public-market record.

Tempus AI (TEM) trades as ordinary local shares, while BioNTech (BNTX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both BioNTech (BNTX) at -8.14% and Tempus AI (TEM) at -37.55% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

Both BioNTech (BNTX) at -60.87% and Tempus AI (TEM) at -12.54% report negative net margin values, usually indicating net losses over the period.

Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile BioNTech (BNTX) reports 30.28%, ranking against industry peers normally.

Profitability Metrics

Growth

Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while BioNTech (BNTX) at 4.32% is closer to the peer norm — faster top-line expansion for TEM.

Neither BioNTech (BNTX) nor Tempus AI (TEM) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Both BioNTech (BNTX) at 8.55 and Tempus AI (TEM) at 2.61 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

BioNTech (BNTX) at 0.02 keeps leverage in the lower quartile, while Tempus AI (TEM) at 2.86 is above its industry debt-to-equity ratio range.

Financial Strength Metrics

Dividends

Neither BioNTech (BNTX) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither BioNTech (BNTX) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Neither BioNTech (BNTX) nor Tempus AI (TEM) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

On P/S ratio, both BioNTech (BNTX) at 8.96 and Tempus AI (TEM) at 9.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BioNTech (BNTX) at 1.09 sits in the lower P/B ratio quartile relative to book while Tempus AI (TEM) at 27.66 prices above its industry range — a wide valuation gap against assets.

Valuation Metrics